2022 WMIF | The Cell Therapy Landscape | CAR-T to Stem Cells
Cell therapies, ranging from CAR-T cells to stem-cell-based approaches, are emerging as a transformative therapeutic modality. Panelists will examine this emerging landscape and discuss a range of key topics. What drives differentiation in this space given the high number of competing technologies? How will the uptake of autologous cell therapies and allogeneic versions evolve? When […]
Study Shows Effectiveness of Merakris’ Wound Care Products
RESEARCH TRIANGLE PARK, N.C., June 02, 2022 (GLOBE NEWSWIRE) — A peer-reviewed case study in the May 21 edition of SAGE Open Medical Case Reports highlights the effectiveness of two Merakris Therapeutics wound care products – Dermacyte® Amniotic Wound Care Liquid and Dermacyte® Amniotic Wound Care Matrix – in treating non-healing venous leg ulcers. The […]
Biorep Technologies, Inc. Joins the Tetra Partner Network to Accelerate Research into Stem-Cell Derived Insulin to Cure Diabetes
BOSTON, May 31, 2022 /PRNewswire/ — TetraScience, the R&D Data Cloud company, announced today that Biorep Technologies, Inc., the leading provider of scientific instruments that help pharmaceutical companies and leading universities research cures for Type 1 and Type 2 diabetes, has joined the Tetra Partner Network. The partnership builds on a joint deployment of Biorep’s […]
Can Induced Pluripotent Stem Cells Regrow Bones & Teeth?
Losing your teeth is something that many people face every day. This not only can affect our self-esteem and physical appearance, but also our health and proper digestion of food. Dentures and implants are a common solution to replace teeth, but what if there was the option to actually regrow teeth? iPS cells or induced […]
FUJIFILM Cellular Dynamics Launches Parkinson’s Disease iCell DopaNeurons featuring LRRK2 and GBA Mutations
MADISON, Wis., May 24, 2022 (GLOBE NEWSWIRE) — FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cell (iPSC) products, announced today the launch of Parkinson’s disease (PD) iCell DopaNeurons featuring LRRK2 (G2019S) and GBA (N370S) mutations, which are common PD risk-associated mutations. These PD iCell DopaNeurons were developed […]
TScan Therapeutics Presents Preclinical Data at the American Society of Gene and Cell Therapy 25th Annual Meeting
WALTHAM, Mass., May 19, 2022 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, presented two posters and an oral presentation around TScan’s proprietary platform technologies for its solid tumor program at […]
Stem Cell Therapy and Strokes – Jason Hinman, MD
In this very important episode of “Life After Stroke with Christopher Ewing”, Christopher speaks with Dr. Jason Hinman, Assistant Professor of Neurology in the Stroke and Neuro-rehabilitation Divisions at the UCLA Stroke Center in Los Angeles, CA. Topics covered in this episode include: – Does stem cell therapy work in stroke survivors? – How is […]
Foundation Fighting Blindness to Host VISIONS 2022 Conference
COLUMBIA, Md., May 12, 2022 /PRNewswire/ — The Foundation Fighting Blindness, the world’s leading organization committed to finding treatments and cures for blinding retinal diseases, will host its VISIONS 2022 national conference at Disney’s Coronado Springs Resort on June 17–18, 2022. This one-of-a-kind biennial event will provide attendees the opportunity to hear about exciting advancements […]
Top 12 Emerging Gene and Cell Therapy Technologies Likely to Impact Patient Care Announced in Annual “Disruptive Dozen” from Mass General Brigham
Boston, MA, May 04, 2022 (GLOBE NEWSWIRE) — Mass General Brigham today revealed the annual “Disruptive Dozen,” 12 emerging gene and cell therapy (GCT) technologies with the greatest potential to impact health care in the next several years. The “Disruptive Dozen” results from interviews of 50 Mass General Brigham senior Harvard faculty followed by a […]
Vitti Labs Announces FDA Approval of Phase II IND Clinical Trial of Combination Mesenchymal Stem Cell and Exosome Treatment of Pulmonary Fibrosis Secondary to Novel Corona Virus Infection (COVID-19)
LIBERTY, Mo., May 2, 2022 /PRNewswire/ — Vitti Labs, an AATB Accredited Tissue Bank focused on life Science Research, development, and manufacturing, announced today that the U.S. Food and Drug Administration (FDA) has approved their Investigational New Drug Application (IND) to move forward with Phase II Outpatient Clinical Trial using a combination of Umbilical Cord […]